Reactivity of sera with MS and MPT51:

<p>Sera from HIV⁻PPD⁻ and HIV⁻PPD⁺ healthy subjects and TB patients were tested for reactivity with MS (A) and MPT51 (B). Mean OD (optical density)±standard deviation is depicted.</p

Presence of anti-MS or anti-MPT51 antibodies in TB patients:

<p>Sera from healthy PPD+/PPD⁻ subjects, healthy community controls (HCC) and TB patients was tested for presence of anti-MS (A) or anti-MPT51 (B) antibodies. Delta OD (optical density) represents the OD obtained with the individual serum specimen minus the mean OD plus 3 standard deviations obtained with the PPD⁺/PPD⁻ healthy subjects. Filled symbols represent results from ELISA assays in which the Invitrogen substrate was used. Delta RLU (relative light units) represents relative light units obtained with the individual serum specimen minus the mean RLU plus 3 standard deviations obtained with sera from PPD⁺/PPD⁻ healthy subjects. Hollow symbols indicate results from ELISA assays in which the PhosphoGLO AP substrate was used. Numbers in parenthesis indicate number of subjects in each group.</p

Presence of anti-MS and/or anti-MPT51 antibodies in HIV⁺TB⁻ subjects at high-risk or low-risk for TB:

<p>Sera from healthy PPD⁺/PPD⁻ subjects, asymptomatic HIV⁺TB⁻ subjects at high-risk for TB (HR) and asymptomatic HIV⁺TB⁻ subjects at low-risk (LR) for TB was tested for presence of anti-MS and -MPT51 antibodies (A). Presence of these biomarkers in sera from HIV⁺TB⁻, HR subjects with different CD4⁺ T cell numbers (B), and in sera from HIV⁺TB⁻, LR subjects with different CD4⁺ T cell numbers (C). In all figures, bars with diagonal lines represent anti-MS and bars with dots represent anti-MPT51 antibodies. Additive reactivity of both biomarkers is represented by solid black bars. Numbers in parenthesis indicate number of subjects in each group.</p

Anti-MS and/or anti-MPT51 antibodies as biomarkers for TB in different categories of patients:

<p>Presence of the two biomarkers in smear-positive HIV⁻TB⁺, smear-negative HIV⁻TB⁺ and smear-positive HIV⁺TB⁺ patients (A). Presence of the biomarkers in HIV⁺TB⁺ patients with CD4⁺ T cell numbers <200/ul or between 201–400 (B). Presence of the biomarkers in HIV⁺TB⁺ patients with pulmonary TB or extrapulmonary TB (C). In all figures, bars with diagonal lines represent anti-MS antibodies, bars with dots represent anti-MPT51 antibodies and additive reactivity with both biomarkers is represented by solid black bars. Numbers in parenthesis indicate number of subjects in each group.</p

Presence of anti-MS &/or –MPT51 antibodies during SCTB in HIV⁺TB⁺ patients

<p>NA: Not available</p

Pre-treatment loss to follow-up rate among MDR-TB suspects before and after diagnosis is in the pre-LPA and post-LPA periods at New Delhi, India.

<p>Pre-treatment loss to follow-up rate among MDR-TB suspects before and after diagnosis is in the pre-LPA and post-LPA periods at New Delhi, India.</p

Demographic characteristics of MDR-TB patients according to the method of MDR-TB diagnosis used between 2009–2012 - New Delhi, India.

a<p>Solid culture & Drug Sensitivity Testing (DST),</p>b<p>LPA: Line Probe Assay, MDR-TB: Multidrug resistant Tuberculosis, IQR: Inter-quartile Range.</p

Comparison of time from identification of patients suspected for MDR-TB to initiation of MDR-TB treatment between pre- and post-LPA period - New Delhi, India.

<p>*P-value generated using the Wilcoxon rank sum test; IQR = Inter-quartile range; MDR-TB = Multidrug resistant Tuberculosis;</p>a<p>Solid/liquid culture & Drug Sensitivity Testing (DST).</p>b<p>LPA: Line Probe Assay.</p